S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.21
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.51
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
ORMP · Oramed Pharmaceuticals Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Oramed Pharmaceuticals Inc (ORMP)
NASDAQ NMS - GLOBAL MARKET
Pharmaceuticals
$4.13
-0.03
(-0.72%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$4.13
$4.08
$4.14
52-WEEK RANGE
$4.13
$2.09
$5.47
What's happening
- ORMP is down 0.72% today, trading at $4.13. — Live quote
- Volume today (3,474) is well below its 3-month average of 261,639. (Finnhub fundamentals)
- Reports earnings on 2026-11-11, 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $1.84 actual vs. $0.44 estimated (+319.5%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 0
Buy 0
Hold 3
Sell 1
Strong sell 2
Aggregate ratings for 2025-06-01 (6 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
ORMP
+45.61%
vs S&P 500
+32.84%
1-YEAR RETURN
ORMP
+81.22%
vs S&P 500
+66.66%
6-MONTH RETURN
ORMP
+7.51%
3-MONTH RETURN
ORMP
+3.23%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$1.84
Est. $0.44
BEAT +319.5%
2026-01-26 (Q4 2025)
$0.24
Est. $0.00
2025-10-26 (Q3 2025)
$1.12
Est. $-0.04
BEAT +2845.1%
2025-07-26 (Q2 2025)
$0.31
Est. $-0.04
BEAT +859.8%
Valuation Measures & Ratios
Enterprise Value4$157.4M
Forward P/E50.92
PEG Ratio6—
Price / Sales (TTM1)43.31
Price / Book70.62
EV4 / Revenue—
EV4 / EBITDA—
Profit Margin-838.40%
Operating Margin-1070.36%
Return on Equity (ROE8)72.96%
Return on Assets (ROA9)64.18%
Avg Volume (3M)261,639
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $203.9M | $144.0M | $105.0M | $86.7M | $80.2M |
| P/E | 1.14 | 1.56 | 3.05 | -18.21 | -4.86 |
| Price/Book | — | — | 0.52 | 0.56 | 0.57 |
| ROE | — | — | 16.93% | -3.08% | -11.73% |
| ROA | 48.19% | 34.35% | 15.61% | -2.94% | -11.19% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short1,433,436
Change from Prior Settlement+9.61%
% of Float—
Days to Cover (Short Ratio)7.33
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Trailing 52-week price return is +81.2%. Finnhub market metrics ↗
- Latest SEC filing is Form 4, filed 2026-10-02; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -100.0% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is -838.4%. Finnhub fundamentals ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on ORMP
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $2.0M | — | — | — |
| Gross profit | — | — | — | — | $13.0K | — | — | — |
| Operating income | -$2.8M | -$3.7M | -$2.4M | -$2.5M | -$4.5M | -$3.1M | -$3.1M | -$3.0M |
| Net income | $78.2M | $38.3M | $48.4M | $13.3M | -$7.6M | -$19.6M | $9.2M | $1.5M |
| EPS (diluted) | $1.84 | $0.91 | $1.13 | $0.31 | $-0.19 | $-0.48 | $0.22 | $0.04 |
| EPS (basic) | $1.90 | $0.94 | $1.16 | $0.32 | $-0.19 | $-0.48 | $0.22 | $0.04 |
| Operating margin | — | — | — | — | -$225 | — | — | — |
| Net margin | — | — | — | — | -$382 | — | — | — |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $369.6M | $268.8M | $230.9M | $220.5M | $161.7M | $147.5M | $155.3M | $165.1M |
| Total liabilities | — | — | — | — | — | — | — | — |
| Stockholders' equity | — | — | $199.7M | $203.3M | $154.5M | $140.8M | $146.3M | $156.4M |
| Total current assets | $53.4M | $68.2M | $133.3M | $136.1M | $99.0M | $131.5M | $143.2M | $142.8M |
| Total current liabilities | $10.7M | $10.6M | $19.1M | $6.1M | $3.7M | $5.5M | $5.7M | $5.3M |
| Cash & equivalents | $15.2M | $13.2M | $45.9M | $52.2M | $15.8M | — | $54.4M | — |
| Marketable securities (current) | $846.0K | $5.0M | $5.4M | $5.0M | $1.8M | $3.7M | $3.4M | $646.0K |
| Accounts receivable | — | — | — | — | — | — | — | — |
| Other current assets | — | — | — | — | — | — | — | — |
| Marketable securities (non-current) | $21.9M | $18.0M | $8.4M | — | — | $3.5M | $3.5M | $646.0K |
| Property, plant & equipment | $532.0K | $561.0K | $586.0K | $614.0K | $645.0K | $671.0K | $698.0K | $718.0K |
| Other non-current assets | $49.0K | $46.0K | $44.0K | $40.0K | $38.0K | $32.0K | $32.0K | — |
| Accounts payable | $374.0K | $481.0K | $443.0K | $560.0K | $715.0K | $509.0K | $789.0K | — |
| Accrued liabilities | $1.3M | $1.1M | $1.1M | $585.0K | $841.0K | $800.0K | $402.0K | — |
| Deferred revenue (current) | $1.7M | $1.5M | $1.4M | — | — | — | — | — |
| Short-term debt | — | — | — | — | — | — | — | — |
| Other current liabilities | — | — | $1.7M | — | — | — | $1.4M | — |
| Long-term debt | — | — | — | — | — | — | — | — |
| Other non-current liabilities | — | — | — | — | — | — | $60.0K | $60.0K |
| Common stock & paid-in capital | $495.0K | $491.0K | $472.0K | $490.0K | $491.0K | $491.0K | $480.0K | $484.0K |
| Retained earnings | -$7.0M | -$85.1M | -$123.4M | -$122.6M | -$171.0M | -$184.3M | -$176.6M | -$166.4M |
| Accumulated other comprehensive income (loss) | — | — | — | — | — | — | — | — |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$200.0K | -$2.9M | -$466.0K | -$1.6M | -$3.5M | -$3.5M | -$1.9M | -$7.1M |
| Investing cash flow | $4.3M | -$19.5M | -$1.7M | $38.4M | -$54.9M | $23.6M | $15.4M | -$34.3M |
| Financing cash flow | -$1.9M | -$10.4M | -$4.0M | -$361.0K | -$371.0K | — | -$1.2M | -$1.3M |
| Free cash flow | -$202.0K | -$2.9M | -$468.0K | -$1.6M | -$3.5M | -$3.5M | -$1.9M | -$7.1M |
| Capital expenditures | $2.0K | $5.0K | $2.0K | $0 | $4.0K | $3.0K | $11.0K | $5.0K |
| Depreciation & amortization | — | — | — | — | — | — | — | — |
| Share-based compensation | $1.4M | $1.7M | $2.3M | $719.0K | $800.0K | $2.2M | $1.2M | $301.0K |
| Deferred income taxes | $21.8M | — | $7.9M | — | — | — | — | — |
| Change in accounts payable | — | — | — | — | — | — | — | — |
| Purchases of investments | $8.7M | $12.9M | $8.3M | $1.5M | — | — | — | — |
| Other investing activities | — | — | — | — | — | — | — | — |
| Dividends paid | $78.0K | $10.4M | — | — | — | — | — | — |
| Share repurchases | — | — | $4.0M | $361.0K | $371.0K | — | $1.2M | $1.3M |
| Tax withholding on stock comp | $352.0K | $1.5M | — | — | — | — | $2.0K | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Aug '21 |
|---|---|---|---|---|---|
| Revenue | $2.0M | — | $1.3M | $2.7M | $2.7M |
| Gross profit | $13.0K | — | — | — | — |
| Operating income | -$15.1M | -$12.8M | -$15.8M | -$40.6M | -$24.2M |
| Net income | $64.0M | -$19.1M | $5.1M | -$36.6M | -$23.0M |
| EPS (diluted) | $1.50 | $-0.48 | $0.14 | $-0.94 | — |
| EPS (basic) | $1.53 | $-0.48 | $0.14 | $-0.94 | — |
| Operating margin | -$754 | — | -$1.2K | -$1.5K | -$896 |
| Net margin | $3.2K | — | $380 | -$1.4K | -$850 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Aug '23 | Dec '22 |
|---|---|---|---|---|---|
| Total assets | $230.9M | $155.3M | $220.6M | — | $161.6M |
| Stockholders' equity | $199.7M | $146.3M | $163.8M | — | $151.8M |
| Total current assets | $133.3M | $143.2M | $162.6M | — | $157.1M |
| Total current liabilities | $19.1M | $5.7M | $53.2M | — | $5.7M |
| Cash & equivalents | $45.9M | $54.4M | $9.1M | — | $40.5M |
| Marketable securities (current) | $5.4M | $3.4M | — | — | $3.7M |
| Accounts receivable | — | — | — | — | — |
| Other current assets | — | — | — | — | — |
| Marketable securities (non-current) | $8.4M | — | $1.8M | — | — |
| Property, plant & equipment | $586.0K | $698.0K | $873.0K | — | $815.0K |
| Other non-current assets | $44.0K | $32.0K | $27.0K | — | — |
| Accounts payable | $443.0K | $789.0K | $551.0K | — | — |
| Accrued liabilities | $1.1M | $402.0K | $605.0K | — | — |
| Short-term debt | — | — | $51.0M | $99.5M | — |
| Other current liabilities | $1.7M | $1.4M | $59.0K | — | $133.0K |
| Long-term debt | — | — | — | — | $25.0K |
| Other non-current liabilities | — | $60.0K | $63.0K | — | — |
| Common stock & paid-in capital | $472.0K | $480.0K | $485.0K | — | $476.0K |
| Retained earnings | -$123.4M | -$176.6M | -$157.6M | — | -$163.1M |
| Accumulated other comprehensive income (loss) | — | — | — | — | — |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Aug '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$9.1M | -$8.4M | -$10.3M | -$27.9M | -$21.2M |
| Investing cash flow | $5.4M | $105.8M | -$73.0M | $30.2M | -$23.8M |
| Financing cash flow | -$4.7M | -$52.0M | $52.0M | $10.8M | $102.9M |
| Free cash flow | -$9.2M | -$8.4M | -$10.5M | -$28.4M | -$21.6M |
| Capital expenditures | $9.0K | $18.0K | $254.0K | $496.0K | $375.0K |
| Depreciation & amortization | — | — | — | — | — |
| Share-based compensation | $6.0M | $4.1M | $4.2M | $11.5M | $2.7M |
| Deferred income taxes | $7.9M | — | — | — | — |
| Change in accounts payable | — | — | — | — | — |
| Purchases of investments | $9.8M | — | — | — | — |
| Other investing activities | — | — | — | — | — |
| Share repurchases | $4.7M | $2.5M | — | — | — |
| Tax withholding on stock comp | — | $2.0K | — | $783.0K | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding ORMP as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-12-31 to 2026-10-01
Recent transactions
- Insiders have net sold 260,360 shares over the last 182 days, across 0 purchases and 4 sales.
- Most recent: Gabay Avraham (Chief Financial Officer) — Open market sale of 20,000 shares on 2026-10-01.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)260,360 sh(4 txns)
Net Shares-260,360
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Gabay Avraham | Chief Financial Officer | Open market sale | 2026-10-01 | 20,000 |
| Hexter Joshua | COO & CBO | Open market sale | 2026-10-01 | 30,000 |
| KIDRON NADAV | President and CEO | Grant / award | 2026-09-24 | 349,497 |
| Kidron Miriam | Chief Scientific Officer | Grant / award | 2026-09-24 | 208,125 |
| Reznick Yehuda | Director | Grant / award | 2025-12-31 | 30,000 |
| Shapiro Benjamin | Director | Grant / award | 2025-12-31 | 30,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-01 | Gabay Avraham | Chief Financial Officer | Open market sale | 20,000 | $4.51 |
| 2026-10-01 | Hexter Joshua | COO & CBO | Open market sale | 30,000 | $4.51 |
| 2026-09-24 | KIDRON NADAV | President and CEO | Grant / award | 349,497 | — |
| 2026-09-24 | KIDRON NADAV | President and CEO | Grant / award | 368,765 | — |
| 2026-09-24 | Hexter Joshua | COO & CBO | Grant / award | 75,455 | — |
| 2026-09-24 | Hexter Joshua | COO & CBO | Grant / award | 209,291 | — |
| 2026-09-24 | Kidron Miriam | Chief Scientific Officer | Grant / award | 208,125 | — |
| 2026-09-24 | Kidron Miriam | Chief Scientific Officer | Grant / award | 209,291 | — |
| 2026-09-24 | Gabay Avraham | Chief Financial Officer | Grant / award | 209,291 | — |
| 2026-07-02 | Hexter Joshua | COO & CBO | Option exercise | 50,000 | $3.69 |
| 2026-07-01 | Hexter Joshua | COO & CBO | Open market sale | 137,000 | $4.46 |
| 2026-07-01 | Gabay Avraham | Chief Financial Officer | Open market sale | 73,360 | $4.51 |
| 2026-03-30 | KIDRON NADAV | President and CEO | Tax withholding | 44,818 | $3.31 |
| 2026-03-30 | Kidron Miriam | Chief Scientific Officer | Tax withholding | 435,084 | $3.31 |
| 2026-03-17 | Kidron Miriam | Chief Scientific Officer | Grant / award | 119,558 | $0.00 |
| 2026-03-17 | KIDRON NADAV | President and CEO | Grant / award | 167,005 | $0.00 |
| 2026-03-17 | Hexter Joshua | COO & CBO | Grant / award | 95,889 | $0.00 |
| 2026-03-17 | Gabay Avraham | Chief Financial Officer | Grant / award | 95,889 | $0.00 |
| 2026-03-12 | KIDRON NADAV | President and CEO | Gift | 100,000 | $0.00 |
| 2026-01-22 | Hexter Joshua | COO & CBO | Option exercise | 19,000 | $0.00 |
| 2026-01-22 | Kidron Miriam | Chief Scientific Officer | Option exercise | 19,000 | $0.00 |
| 2026-01-22 | Gabay Avraham | Chief Financial Officer | Option exercise | 19,000 | $0.00 |
| 2026-01-22 | KIDRON NADAV | President and CEO | Option exercise | 109,000 | $0.00 |
| 2026-01-14 | Kidron Miriam | Chief Scientific Officer | Gift | 86,166 | $0.00 |
| 2025-12-31 | Reznick Yehuda | Director | Grant / award | 30,000 | — |
| 2025-12-31 | Reznick Yehuda | Director | Grant / award | 6,250 | — |
| 2025-12-31 | KIDRON NADAV | President and CEO | Grant / award | 232,640 | $0.00 |
| 2025-12-31 | KIDRON NADAV | President and CEO | Grant / award | 327,000 | $0.00 |
| 2025-12-31 | Kidron Miriam | Chief Scientific Officer | Grant / award | 121,331 | $0.00 |
| 2025-12-31 | Kidron Miriam | Chief Scientific Officer | Grant / award | 115,000 | $0.00 |
| 2025-12-31 | Hexter Joshua | COO & CBO | Grant / award | 97,328 | $0.00 |
| 2025-12-31 | Hexter Joshua | COO & CBO | Grant / award | 115,000 | $0.00 |
| 2025-12-31 | Shapiro Benjamin | Director | Grant / award | 30,000 | — |
| 2025-12-31 | Shapiro Benjamin | Director | Grant / award | 3,500 | — |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-21 23:39 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-02 | 4 | 2026-10-01 | View on SEC.gov → |
| 2026-10-02 | 4 | 2026-10-01 | View on SEC.gov → |
| 2026-09-25 | 4 | 2026-09-24 | View on SEC.gov → |
| 2026-09-25 | 4 | 2026-09-24 | View on SEC.gov → |
| 2026-09-25 | 4 | 2026-09-24 | View on SEC.gov → |
| 2026-09-25 | 4 | 2026-09-24 | View on SEC.gov → |
| 2026-09-17 | 8-K | 2026-09-15 | View on SEC.gov → |
| 2026-08-10 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-07-02 | 4 | 2026-07-01 | View on SEC.gov → |
| 2026-07-02 | 4 | 2026-07-01 | View on SEC.gov → |
| 2026-06-30 | 8-K | 2026-06-25 | View on SEC.gov → |
| 2026-05-19 | 10-Q | 2026-03-31 | View on SEC.gov → |
Recent news
Headlines about ORMP (Oramed Pharmaceuticals Inc.). Links open the publisher — we don’t host full articles.
-
Barron's lists USD 7.00 target for Oramed Pharmaceuticals stock
AD HOC NEWS · 2026-10-20 -
Oramed Pharmaceuticals Inc. Stock Price Prediction: Today, Tomorrow, Next Week (ORMP)
Traders Union · 2026-10-20 -
Barron's lists USD 7.00 target for Oramed Pharmaceuticals stock - ad-hoc-news.de
ad-hoc-news.de · 2026-10-17 -
ORMP270219P00005000 Interactive Stock Chart | ORMP Feb 2027 5.000 put Stock
Yahoo Finance · 2026-10-16 -
ORMP Nov 2026 7.500 put (ORMP261120P00007500) Interactive Stock Chart - Yahoo Finance
Yahoo! Finance Canada · 2026-10-16 -
ORMP May 2027 5.000 call (ORMP270521C00005000) stock price, news, quote and history
Yahoo Finance Australia · 2026-10-16 -
ORMP Nov 2026 7.500 call (ORMP261120C00007500) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-16 -
Oramed Pharmaceuticals schedules November 12 results for Oramed Pharmaceuticals stock - ad-hoc-news.de
ad-hoc-news.de · 2026-10-15
No headlines in this category right now — try “All”.